We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Ranked Momentum Stocks to Buy for December 30th
Read MoreHide Full Article
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th:
HealthEquity, Inc. (HQY - Free Report) : This company that provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25% over the last 60 days.
Sony Corporation : This company that designs, develops, produces, and sells electronic equipment, instruments, and devices for the consumer, professional, and industrial markets has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.7% over the last 60 days.
Bristol-Myers Squibb Company (BMY - Free Report) : This company that discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.2% over the last 60 days.
Adaptive Biotechnologies Corporation (ADPT - Free Report) : This company that develops an immune medicine platform for the diagnosis and treatment of various diseases has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 55.3% over the last 60 days.
Adaptive Biotechnologies Corporation Price and Consensus
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Top Ranked Momentum Stocks to Buy for December 30th
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th:
HealthEquity, Inc. (HQY - Free Report) : This company that provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25% over the last 60 days.
HealthEquity, Inc. Price and Consensus
HealthEquity, Inc. price-consensus-chart | HealthEquity, Inc. Quote
HealthEquity’s shares gained 20.3% over the last one month above the S&P 500’s increase 4.1%. The company possesses a Momentum Score of B.
HealthEquity, Inc. Price
HealthEquity, Inc. price | HealthEquity, Inc. Quote
Sony Corporation : This company that designs, develops, produces, and sells electronic equipment, instruments, and devices for the consumer, professional, and industrial markets has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.7% over the last 60 days.
Sony Corporation Price and Consensus
Sony Corporation price-consensus-chart | Sony Corporation Quote
Sony’s shares gained 7.1% over the last one month. The company possesses a Momentum Score of B.
Sony Corporation Price
Sony Corporation price | Sony Corporation Quote
Bristol-Myers Squibb Company (BMY - Free Report) : This company that discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.2% over the last 60 days.
Bristol-Myers Squibb Company Price and Consensus
Bristol-Myers Squibb Company price-consensus-chart | Bristol-Myers Squibb Company Quote
Bristol-Myers Squibb’s shares gained 11.7% over the last one month. The company possesses a Momentum Score of A.
Bristol-Myers Squibb Company Price
Bristol-Myers Squibb Company price | Bristol-Myers Squibb Company Quote
Adaptive Biotechnologies Corporation (ADPT - Free Report) : This company that develops an immune medicine platform for the diagnosis and treatment of various diseases has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 55.3% over the last 60 days.
Adaptive Biotechnologies Corporation Price and Consensus
Adaptive Biotechnologies Corporation price-consensus-chart | Adaptive Biotechnologies Corporation Quote
Adaptive Biotechnologies’ shares gained 6.4% over the last one month. The company possesses a Momentum Score of B.
Adaptive Biotechnologies Corporation Price
Adaptive Biotechnologies Corporation price | Adaptive Biotechnologies Corporation Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>